Literature DB >> 27067884

Hemostatic Markers and Long-Term Risk of Intracerebral Hemorrhage in Postmenopausal Women.

Ju-Mi Lee1, Juned Siddique2, Hyeon Chang Kim1, David Green2, Linda Van Horn2, Matthew Allison3, Sylvia Wassertheil-Smoller4, Philip Greenland5.   

Abstract

BACKGROUND: Known risk factors for intracerebral hemorrhage (ICH) include age, hypertension, smoking, alcohol intake, and anticoagulant use. Some previous reports have indicated that hemostatic factors measured many years before the onset of ICH might predict the later occurrence of ICH. The objective of this analysis was to test whether selected hemostatic factors measured years before the onset of ICH could identify patients at higher risk for future ICH.
METHODS: We performed a nested case-control study within the Women's Health Initiative (WHI) cohort. Postmenopausal women aged 50-79 years (mean 68) at baseline (1993-1998) were enrolled at 40 Clinical Centers in the United States and followed for adjudicated ICH for a mean of 11.4 years. ICH cases (N = 75) and controls (N = 75) were matched on age, ethnicity, blood pressure, anticoagulant use, and treated hypertension. Stored blood samples from the baseline WHI examination were tested for von Willebrand factor (vWF), a disintegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13 (ADAMTS13), tissue plasminogen activator (t-PA), and urokinase plasminogen activator (u-PA). Platelet count, white blood cell count, and hemoglobin concentration were also measured.
RESULTS: Mean baseline levels of vWF (1.03 and .95 U/mL), ADAMTS13 (1.0 and 1.1 µg/mL), vWF : ADAMTS13 ratio (.99 and .92), t-PA (14.75 and 14.80 IU/mL), and u-PA (.09 and .10 IU/mL) were not significantly different by case-control status. Significant differences were also not identified for platelet count, hemoglobin, white blood count, or reported alcohol use.
CONCLUSION: None of the 4 baseline hemostatic factors nor the platelet count was predictive of future ICH risk in this long-term study of older postmenopausal women.
Copyright © 2016 National Stroke Association. All rights reserved.

Entities:  

Keywords:  ADAMTS13; Cerebral hemorrhage; plasminogen activators; von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 27067884      PMCID: PMC4912397          DOI: 10.1016/j.jstrokecerebrovasdis.2016.03.013

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  21 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Association between cardiovascular outcomes and antihypertensive drug treatment in older women.

Authors:  Sylvia Wassertheil-Smoller; Bruce Psaty; Philip Greenland; Albert Oberman; Theodore Kotchen; Charles Mouton; Henry Black; Aaron Aragaki; Maurizio Trevisan
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

3.  From clinical observation to mechanism--Heyde's syndrome.

Authors:  Joseph Loscalzo
Journal:  N Engl J Med       Date:  2012-11-15       Impact factor: 91.245

Review 4.  Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.

Authors:  Jessica Blavignac; Natalia Bunimov; Georges E Rivard; Catherine P M Hayward
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

5.  Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage.

Authors:  M D I Vergouwen; V L Knaup; J J T H Roelofs; O J de Boer; J C M Meijers
Journal:  J Thromb Haemost       Date:  2014-06       Impact factor: 5.824

6.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

7.  Risk factors for intracerebral hemorrhage in a pooled prospective study.

Authors:  Jared D Sturgeon; Aaron R Folsom; W T Longstreth; Eyal Shahar; Wayne D Rosamond; Mary Cushman
Journal:  Stroke       Date:  2007-08-30       Impact factor: 7.914

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

9.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 10.  Latest advances in intracerebral hemorrhage.

Authors:  Marc Ribo; James C Grotta
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.